Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Choosing between a stock index and an index fund depends on costs, flexibility, and your investment objectives. This article compares the options clearly.
25,679 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Looking for dividend stocks with real upside? This guide highlights two dependable names that could help you double y...
Insider trades can hint at a company's future, but not every move is meaningful. This article shows how to filter sig...
Symbotic's shiny narrative has investors buzzing, but the biggest gains often hinge on real execution, not just optim...
A wave of new positions from hedge funds loading boeing points to a cautious but growing bet that Boeing can rebound ...
AMD sits near a pivotal $420 level as first-quarter results underscore strong data-center demand and a bold AI-driven...
Through May 2026, CWB rose about 19% year-to-date, underscoring the appeal of convertible bonds as a middle ground be...
Bark is shaping its path in a competitive pet market. This guide breaks down what to expect in bark (bark) 2026 earni...
When a veteran value investor piles into a beaten-down name, traders take notice. Prem Watsa recently added to his Un...
While Nvidia grabs the spotlight with GPUs, Broadcom quietly powers AI at scale with custom accelerators. This articl...
A Parabilis Medicines director recently disclosed a substantial stake just after the company’s fresh IPO. This articl...
After closing on a rental property, one diligence item can determine whether your cash flow meets expectations. This ...